Astria Therapeutics Inc
NASDAQ:ATXS
Astria Therapeutics Inc
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2015-06-25. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2015-06-25. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.
Phase I Data: Astria reported positive Phase Ia data for STAR-0215, supporting its potential as a first choice preventative treatment for hereditary angioedema (HAE).
Dosing Options: Both 3- and 6-month dosing regimens for STAR-0215 showed robust attack suppression and low treatment burden, with high interest from patients and physicians.
Pipeline Expansion: The company announced the addition of STAR-0310, targeting atopic dermatitis, with key preclinical and IND milestones planned for 2024.
Accelerated Timelines: Faster-than-expected enrollment in the ALPHA STAR trial allows for initial proof-of-concept data in HAE patients to be shared in Q1 2024.
Financial Position: Astria ended Q3 2023 with $188.8 million in cash and closed a $64 million offering in October, expecting to fund operations into 2026.
Upcoming Milestones: Key readouts and filings are expected for both STAR-0215 and STAR-0310 through 2024 and 2025.
